Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2014-11-07 Interim / Quarterly Rep…
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q1 2014
2014-11-07 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PRELIMINARY PROXY STATEMENT' and is filed as a Schedule 14A with the SEC, which is a proxy solicitation document. It includes an invitation to the 2014 annual meeting of stockholders, details on proposals to be voted on (e.g., election of directors, stock option plan approval, amendment to Articles of Incorporation, advisory votes on executive compensation, and appointment of independent auditors). It also contains a Notice of Annual Meeting and instructions on voting. The document is not the actual annual report or financial statements but rather the proxy materials sent to shareholders to inform them and solicit their votes for the upcoming meeting. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or a brief notice.
2014-11-05 English
Regulatory Filings 2014
Regulatory Filings
2014-11-03 English
AMENDMENT TO REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the company's securities offering, including the number of shares, pricing, selling stockholders, risk factors, business overview, management discussion, and financial statements. This type of filing is related to capital raising activities and securities registration rather than a financial report, earnings release, or management discussion alone. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a proxy statement, voting results, or governance information. The document is a registration statement amendment for a securities offering, which falls under Capital/Financing Update (CAP) category as it relates to fundraising and capital structure changes.
2014-10-16 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Relmada Therapeutics, Inc. to the SEC responding to comments on an Amendment No. 1 to a Registration Statement on Form S-1 filed on September 16, 2014. It discusses detailed responses to SEC comments on disclosures in the prospectus, including financial statements, business description, risk factors, and audit reports. The presence of a Registration Statement on Form S-1 and detailed responses to SEC comments indicate this is a regulatory filing related to a securities offering registration process. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement or certification. It is a correspondence letter responding to SEC comments on a registration statement, which fits best under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2014-10-16 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions a press release about gross proceeds from the exercise of Series A Warrants, indicating a financing-related update. There is no detailed financial statement or comprehensive report content, just a brief announcement and a press release attached. The document length is 2923 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2014-10-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.